Making the right choices in drug development often means the difference between getting a new medication to patients and it ending up in the scrap heap of failed programs. There is a surfeit of publically available information on approved drugs as well as those currently in development. How can sponsors turn clinical trial data into […]Read More
Author: Mark Lovern
Dr. Mark Lovern recently joined Quantitative Solutions with 14 years of experience in applying modeling and simulation tools and techniques toward optimally informing drug development decision-making. Mark’s previous work history has been split approximately equally between biopharmaceutical companies (GSK and UCB) and companies that support the biopharmaceutical industry (Quintiles and Pharsight). In addition to modeling pharmacokinetic and pharmacodynamic data across a wide variety of compounds and therapeutic areas, Mark has also taught over 50 technical training workshops on modeling tools and methodology. His most recent therapeutic area experience has been with therapies for infectious disease and autoimmune disorders. Mark was awarded a Ph.D. in Biomathematics from the North Carolina State University in 1997. His favorite leisure activities include hosting dinner parties, traveling, reading, and enjoying films.